-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This collaboration will build on Boehringer Ingelheim’s precise psychiatric treatment methods based on brain circuits to develop a comprehensive clinical research plan for major depression and schizophrenia, and further consolidate the provision for people with severe mental illness The promise of better treatment
Ingelheim, Germany and London, England, November 3, 2021/PRNewswire/ - Boehringer Ingelheim and the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London announced a new collaboration on September 27 , The collaboration focused on understanding the brain circuit dysfunction of major depression (MDD) and schizophrenia (SZ), which can lead to cognitive impairment in patients
"We are very pleased to cooperate with IoPPN, a leading psychiatric research institution, King's College London," said Dr.
The collaboration plans to carry out four clinical studies to evaluate the behavior of MDD and SZ patients in the home environment and in the research center.
"King's College London has long focused on advancing the understanding of brain circuits that cause cognitive deficits in mental and neurological disorders," said Professor Steven Williams, head of the IoPPN project at King's College and head of the Department of Neuroimaging
Neuropsychiatric diseases affect hundreds of millions of people around the world, and may affect people's health and their ability to learn and work
[i] GBD 2016 Neurology Collaborators (2019).
[ii] MacEwan J, Seabury S, Aigbogun M, et al (2016).
In the field of Boehringer Ingelheim's mental health, we are redefining mental health so that people can live vibrant lives
Boehringer Ingelheim
Boehringer Ingelheim is committed to researching breakthrough therapies aimed at improving the health of humans and animals
King's College London is one of the top 10 British universities in the world (QS World University Rankings, 2018/19) and one of the oldest universities in England
The Institute of Psychiatry, Psychology and Neuroscience at King's College London (IoPPN) is Europe's premier mental health and related neuroscience research center
Source: Boehringer Ingelheim
